Patents by Inventor James Xin Sun
James Xin Sun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240093235Abstract: Disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines, including vectors and methods for a homologous prime/boost vaccination strategy, such as adenoviral vectors for use in a homologous prime/boost vaccination strategy.Type: ApplicationFiled: December 3, 2021Publication date: March 21, 2024Inventors: Karin Jooss, Ciaran Daniel Scallan, Leonid Gitlin, Andrew Ferguson, Raphael Rousseau, Roman Yelensky, James Xin Sun, Matthew Joseph Davis, Amy Rachel Rappaport, Christine Denise Palmer
-
Publication number: 20240050550Abstract: Disclosed herein are compositions that include antigen-encoding nucleic acid sequences and/or antigen peptides. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines, including vectors and methods for a heterologous prime/boost vaccination strategy.Type: ApplicationFiled: October 3, 2022Publication date: February 15, 2024Inventors: Andrew Ferguson, Raphael Rousseau, Roman Yelensky, James Xin Sun, Matthew Joseph Davis, Karin Jooss, Amy Rachel Rappaport, Ciaran Daniel Scallan, Leonid Gitlin, Christine Denise Palmer
-
Patent number: 11771747Abstract: Disclosed herein are compositions that include antigen-encoding nucleic acid sequences having multiple iterations of KRAS neoepitope-encoding sequences and/or lacking immunodominant epitopes. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines.Type: GrantFiled: April 22, 2022Date of Patent: October 3, 2023Assignee: Gritstone Bio, Inc.Inventors: Karin Jooss, Roman Yelensky, James Xin Sun, Amy Rachel Rappaport, Ciaran Daniel Scallan, Leonid Gitlin, Christine Denise Palmer, Monica Lane
-
Patent number: 11725247Abstract: Methods and compositions for treating cancer such as melanomas are disclosed.Type: GrantFiled: February 27, 2017Date of Patent: August 15, 2023Assignees: FOUNDATION MEDICINE, INC., VANDERBILT UNIVERSITYInventors: Garrett Michael Frampton, Roman Yelensky, James Xin Sun, Douglas Buckner Johnson, Christine Marie Lovly, Jeffrey Alan Sosman, David Fabrizio, Philip James Stephens, Vincent A. Miller
-
Publication number: 20230128001Abstract: Disclosed herein are compositions that include antigen-encoding nucleic acid sequences and/or antigen peptides. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines against infectious diseases such as HIV.Type: ApplicationFiled: August 3, 2022Publication date: April 27, 2023Inventors: Roman Yelensky, James Xin Sun, Joshua Klein, Karin Jooss, Ciaran Daniel Scallan, Leonid Gitlin
-
Publication number: 20230104840Abstract: Methods and compositions for monitoring mutation burden, cancer status, vaccine efficacy using cell-free DNA sequencing are disclosed.Type: ApplicationFiled: July 8, 2022Publication date: April 6, 2023Applicant: Gritstone bio, Inc.Inventors: James Xin Sun, Matthew Joseph Davis, Desiree Schenk, Daniel Navarro Gomez
-
Publication number: 20230041030Abstract: Provided herein are target HLA-PEPTIDE antigens, e.g., HLA-PEPTIDE neoantigens and shared tumor HLA-PEPTIDE antigens, and antigen binding proteins (ABPs) that bind the target HLA-PEPTIDE antigens. Also disclosed are methods for identifying target HLA-PEPTIDE antigens as well as identifying one or more antigen binding proteins that bind a given HLA-PEPTIDE target antigen.Type: ApplicationFiled: May 13, 2022Publication date: February 9, 2023Inventors: Karin Jooss, Aleksandra Katarzyna Nowicka, Abubakar Jalloh, Roman Yelensky, James Xin Sun, Jennifer Busby, Matthew Joseph Davis
-
Publication number: 20230020089Abstract: Disclosed herein are compositions that include antigen-encoding nucleic acid sequences and/or antigen peptides. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines, including vectors and methods for a heterologous prime/boost vaccincation strategy.Type: ApplicationFiled: May 4, 2022Publication date: January 19, 2023Inventors: Andrew Ferguson, Raphael Rousseau, Roman Yelensky, James Xin Sun, Matthew Joseph Davis, Karin Jooss, Amy Rachel Rappaport, Ciaran Daniel Scallan, Leonid Gitlin, Christine Denise Palmer, Jennifer Busby, Brendan Bulik-Sullivan, Mojca Skoberne, Wade Blair
-
Publication number: 20220412981Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g.Type: ApplicationFiled: March 4, 2022Publication date: December 29, 2022Inventors: David FABRIZIO, Garrett M. FRAMPTON, Priti HEGDE, Marcin KOWANETZ, David SHAMES, Philip J. STEPHENS, James Xin SUN, Roman YELENSKY, Wei ZOU
-
Publication number: 20220265797Abstract: Disclosed herein are compositions that include antigen-encoding nucleic acid sequences having multiple iterations of KRAS neoepitope-encoding sequences and/or lacking immunodominant epitopes. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines.Type: ApplicationFiled: April 22, 2022Publication date: August 25, 2022Inventors: Karin Jooss, Roman Yelensky, James Xin Sun, Amy Rachel Rappaport, Ciaran Daniel Scallan, Leonid Gitlin, Christine Denise Palmer, Monica Lane
-
Publication number: 20220265812Abstract: Disclosed herein are compositions that include antigen-encoding nucleic acid sequences and/or antigen peptides. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines against infectious diseases such as HIV.Type: ApplicationFiled: December 29, 2021Publication date: August 25, 2022Inventors: Roman Yelensky, James Xin Sun, Joshua Klein, Karin Jooss, Ciaran Daniel Scallan, Leonid Gitlin
-
Publication number: 20220153861Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).Type: ApplicationFiled: February 2, 2022Publication date: May 19, 2022Inventors: Richard BOURGON, David FABRIZIO, Gregg FINE, Garrett M. FRAMPTON, Priti HEGDE, Sanjeev MARIATHASAN, Philip J. STEPHENS, James Xin SUN, Roman YELENSKY
-
Patent number: 11300570Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g.Type: GrantFiled: April 1, 2019Date of Patent: April 12, 2022Assignees: Genentech, Inc., Foundation Medicine, Inc.Inventors: David Fabrizio, Garrett M. Frampton, Priti Hegde, Marcin Kowanetz, David Shames, Philip J. Stephens, James Xin Sun, Roman Yelensky, Wei Zou
-
Patent number: 11279767Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).Type: GrantFiled: August 28, 2018Date of Patent: March 22, 2022Assignees: Genentech, Inc., Foundation Medicine, Inc.Inventors: Richard Bourgon, David Fabrizio, Gregg Fine, Garrett M. Frampton, Priti Hegde, Sanjeev Mariathasan, Philip J. Stephens, James Xin Sun, Roman Yelensky
-
Publication number: 20210196806Abstract: Disclosed herein are compositions that include antigen-encoding nucleic acid sequences and/or antigen peptides. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines.Type: ApplicationFiled: May 23, 2019Publication date: July 1, 2021Inventors: Roman Yelensky, James Xin Sun, Michele Busby, Jennifer Busby, Brendan Bulik-Sullivan, Mojca Skoberne, Wade Blair, Karin Jooss
-
Publication number: 20210043274Abstract: Methods and systems for analyzing genetic variants are disclosed.Type: ApplicationFiled: October 22, 2020Publication date: February 11, 2021Applicant: Foundation Medicine, Inc.Inventors: James Xin SUN, Roman YELENSKY
-
Patent number: 10847249Abstract: Methods and systems for analyzing genetic variants are disclosed.Type: GrantFiled: September 19, 2017Date of Patent: November 24, 2020Assignee: FOUNDATION MEDICINE, INC.Inventors: James Xin Sun, Roman Yelensky
-
Publication number: 20190219586Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g.Type: ApplicationFiled: April 1, 2019Publication date: July 18, 2019Inventors: David Fabrizio, Garrett M. Frampton, Priti Hegde, Marcin Kowanetz, David Shames, Philip J. Stephens, James Xin Sun, Roman Yelensky, Wei Zou
-
Publication number: 20190085403Abstract: Methods and compositions for treating cancer such as melanomas are disclosed.Type: ApplicationFiled: February 27, 2017Publication date: March 21, 2019Inventors: Garrett Michael Frampton, Roman Yelensky, James Xin Sun, Douglas Buckner Johnson, Christine Marie Lovly, Jeffrey Alan Sosman
-
Publication number: 20180371099Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).Type: ApplicationFiled: August 28, 2018Publication date: December 27, 2018Inventors: Richard BOURGON, David FABRIZIO, Gregg FINE, Garrett M. FRAMPTON, Priti HEGDE, Sanjeev MARIATHASAN, Philip J. STEPHENS, James Xin SUN, Roman YELENSKY